Antiviral drug favipiravir manufactured by the JV of the Russian direct investment Fund (RDIF) and the company “Chemrar” will be examined among patients hospitalized with coronavirus infection. Clinical study will take place in 17 hospitals in several regions of Russia, have informed in the Ministry of health.
“The Ministry of health of Russia issued Russian pharmaceutical manufacturer permission to conduct adaptive multicenter randomized comparative open clinical study of the efficacy and safety of antiviral drug favipiravir patients admitted with COVID-19”, – stated in the message of Ministry of health.
Antiviral drug favipiravir was developed by company Fujifilm. During the outbreak of Ebola in 2014-2015 favipiravir was approved for use in infected patients in Guinea. According to the researches, held in China, against the background of the drug has been shown to reduce the time period during which the coronavirus remains in the body of patients, from 11 to four days. It was also noted the improvement in the affected lung in 91% of patients compared to 62% of control patients not receiving the drug.
At the end of March 2020 the Supervisory Board of the FUND approved the creation of a joint venture (JV) with a group of companies “Chemrar” for the production of favipiravir and other sorts of innovative medicines, including based on it.